Lexaria Bioscience Corp. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Commitments Significant Contracts and Contingencies (Tables)

Commitments Significant Contracts and Contingencies (Tables)

6 Months Ended

Feb. 28, 2023

Commitments Significant Contracts and Contingencies

Schedule of operating lease liabilities

		February 28, 2023				August 31, 2022
Right of use assets - operating leases		$	52,444			$	91,041
Amortization			(20,397	)			(38,597	)
Total lease assets		$	32,047			$	52,444

Liabilities:		$	49,988			$	89,393
Lease payments			(20,397	)			(44,600	)
Interest accretion			(511	)			5,195
Total lease liabilities		$	29,080			$	49,988

Operating lease cost		$	32,047			$	52,444
Operating cash flows for lease		$	20,397			$	44,599
Remaining lease term		0.59 Years				1.17 Years
Discount rate			7.25	%			7.25	%

Schedule of maturities of operating lease liabilities

2023 (six months remaining)			22,408
2024			7,469
Thereafter			-
Total lease payments			29,877
Less: imputed interest			(797	)
Present value of operating lease liabilities			29,080
Less: current obligations under leases			(29,080	)
Total			-